NYSE · RDY
Healthcare · Drug Manufacturers - Specialty & Generic
$13.75
Up+$0.54 (+4.09%)
Updated Oct 27, 2026, 8:59 AM
SID Score
6.2/10
Composite research score
Smart Money
58/100
Neutral
Price performance · RDY
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 26, 2026
RDY closed at $13.75 after 21 trading sessions, up 9.91% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 26, 2026 | $13.595 | $13.855 | $13.595 | $13.75 | 4.12M |
| Oct 23, 2026 | $13.52 | $13.57 | $13.175 | $13.21 | 3.91M |
| Oct 22, 2026 | $13.11 | $13.29 | $13.055 | $13.23 | 3.98M |
| Oct 21, 2026 | $13.24 | $13.24 | $13.15 | $13.19 | 2.11M |
| Oct 20, 2026 | $13.21 | $13.35 | $13.175 | $13.26 | 4.23M |
| Oct 19, 2026 | $13.05 | $13.12 | $13.015 | $13.08 | 1.5M |
| Oct 16, 2026 | $13.00 | $13.07 | $12.935 | $13.07 | 2.79M |
| Oct 15, 2026 | $12.89 | $13.04 | $12.84 | $12.90 | 2.75M |
| Oct 14, 2026 | $12.70 | $12.94 | $12.65 | $12.75 | 3.74M |
| Oct 13, 2026 | $12.92 | $12.95 | $12.74 | $12.77 | 2.72M |
| Oct 12, 2026 | $12.60 | $12.99 | $12.60 | $12.82 | 2.16M |
| Oct 9, 2026 | $12.33 | $12.53 | $12.33 | $12.48 | 1.97M |
| Oct 8, 2026 | $12.07 | $12.29 | $11.99 | $12.20 | 3.83M |
| Oct 7, 2026 | $12.40 | $12.40 | $12.215 | $12.27 | 3.12M |
| Oct 6, 2026 | $12.38 | $12.555 | $12.31 | $12.49 | 4M |
| Oct 5, 2026 | $12.25 | $12.34 | $12.16 | $12.32 | 2.74M |
| Oct 2, 2026 | $12.29 | $12.31 | $12.075 | $12.25 | 3.8M |
| Oct 1, 2026 | $12.38 | $12.55 | $12.24 | $12.25 | 3.17M |
| Sep 30, 2026 | $12.72 | $12.75 | $12.525 | $12.62 | 3.94M |
| Sep 29, 2026 | $12.91 | $12.99 | $12.74 | $12.85 | 4.8M |
| Sep 28, 2026 | $12.44 | $12.67 | $12.43 | $12.51 | 4.03M |
The latest Smart Investors Daily articles mentioning RDY.
Company
Market Activity
Research & News
RDY research
Company profile and research snapshot.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 6, 2021 | Sharekhan | Buy | — |
| Jul 28, 2021 | Motilal Oswal | Neutral | — |
| Jul 28, 2021 | Axis Direct | Buy | — |
| Jul 28, 2021 | Prabhudas Lilladher | Accumulate | — |
| Jul 28, 2021 | ICICI Securities Limited | Hold | — |
No generated briefing is available yet.
ChartMill · Feb 27, 2026
DR. Reddy's Laboratories fits Peter Lynch's GARP strategy with strong earnings growth, low debt, and a reasonable PEG ratio, making it a potential long-term compounder.
Yahoo · Feb 20, 2026
HYDERABAD, India, February 20, 2026--Dr. Reddy’s announces USFDA acceptance to review its Biologics License Application (BLA) for proposed interchangeable biosimilar, Abatacept.
Benzinga · Feb 20, 2026
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's"), today announced that the US Food and Drug Administration (USFDA)
Benzinga · Feb 2, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning RDY.
